WuXi Biologics (Cayman) Inc. Stock price

Equities

2269

KYG970081173

Pharmaceuticals

Market Closed - Hong Kong S.E. 04:08:03 2024-03-28 am EDT 5-day change 1st Jan Change
14.3 HKD +3.92% Intraday chart for WuXi Biologics (Cayman) Inc. +0.70% -51.69%

Financials

Sales 2023 17.03B 2.36B 18.46B Sales 2024 * 18.49B 2.56B 20.03B Capitalization 55.1B 7.63B 59.7B
Net income 2023 3.4B 471M 3.68B Net income 2024 * 3.96B 549M 4.3B EV / Sales 2023 6.67 x
Net cash position 2023 * 3.64B 504M 3.94B Net cash position 2024 * 7.02B 972M 7.6B EV / Sales 2024 * 2.6 x
P/E ratio 2023
34.9 x
P/E ratio 2024 *
14.1 x
Employees 12,740
Yield 2023 *
-
Yield 2024 *
-
Free-Float 85.83%
More Fundamentals * Assessed data
Dynamic Chart
1 day+3.92%
1 week+0.70%
Current month-24.89%
1 month-22.54%
3 months-50.52%
6 months-67.57%
Current year-51.69%
More quotes
1 week
13.04
Extreme 13.04
15.00
1 month
12.94
Extreme 12.94
21.95
Current year
12.94
Extreme 12.94
33.40
1 year
12.94
Extreme 12.94
56.70
3 years
12.94
Extreme 12.94
148.00
5 years
12.94
Extreme 12.94
148.00
10 years
8.33
Extreme 8.3333
148.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 52 11-05-31
Director of Finance/CFO 54 21-08-22
Chief Tech/Sci/R&D Officer 57 -
Members of the board TitleAgeSince
Director/Board Member 73 23-05-05
Director/Board Member 75 17-05-16
Chairman 56 10-04-30
More insiders
Date Price Change Volume
24-03-28 14.3 +3.92% 83,121,160
24-03-27 13.76 +1.47% 59,194,250
24-03-26 13.56 -3.28% 40,185,730
24-03-25 14.02 +7.52% 77,331,720
24-03-22 13.04 -8.17% 83,460,820

Delayed Quote Hong Kong S.E., March 28, 2024 at 04:08 am EDT

More quotes
WuXi Biologics Cayman Inc is an investment holding company principally engaged in provision of discovery, development and manufacturing services of biologics. Through fully-integrated biologics Contract Research, Development and Manufacturing Organization (CRDMO), the Company provides one-stop end-to-end biologics services. Biologics development process stages include pre-IND (drug discovery and pre-clinical development), early-phase (phases I & II) clinical development, late-phase (phase III) clinical development and commercial manufacturing. The Company also offers end-to-end vaccine CRDMO services, including vaccine discovery and development, scale-up commercial manufacturing and global distribution. The Company has WuXiBody bispecific antibody platform, SDArBodY multispecific antibody platform, WuXia cell line development platform, WuXiUP continuous manufacturing platform and mRNA vaccine platform. The Company mainly operates its businesses in the domestic and overseas markets.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
31
Last Close Price
13.21 CNY
Average target price
34.71 CNY
Spread / Average Target
+162.87%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock
  2. Equities
  3. Stock WuXi Biologics (Cayman) Inc. - Hong Kong S.E.